Trump-backed ibogaine study for PTSD receives federal funding

Federal funding for ibogaine research

Federal authorities announced initial funding to explore the clinical potential of ibogaine, a psychedelic compound, for treating post-traumatic stress disorder (PTSD) in veterans. According to the Independent, Health Secretary Robert F. Kennedy Jr. confirmed that up to $4.9 million will be allocated to prepare for the first U.S. trials of ibogaine for PTSD, a condition linked to high rates of suicide and substance abuse among veterans.

Research preparation, not direct trials

The funding will not directly support patient research but will lay the groundwork for producing, dosing, and designing clinical evaluations of ibogaine. Kennedy emphasized that this initiative aims to accelerate the clinical trial process. Ibogaine, derived from a West African shrub, is known for causing intense hallucinations and other severe side effects, and remains illegal under federal law, classified alongside LSD and ecstasy.

Support from veterans and psychedelic advocates

Veterans groups and advocates argue that ibogaine holds promise for treating PTSD, major depression, and opioid dependence. Research in the U.S. has been limited due to its legal status. Kennedy mentioned that the Health and Human Services Department will use guidelines and data from Beond Inc., a Texas company that has treated over 3,000 people with ibogaine in Mexico, where it is not banned.

Why it matters

The announcement follows an executive order from former President Donald Trump in April, directing federal agencies to expedite research into psychedelics for mental health disorders. Veterans Affairs Secretary Doug Collins highlighted the project's focus on safety and high-quality research. This initiative reflects growing interest in psychedelic therapies, with the FDA currently reviewing applications for drugs derived from psilocybin and MDMA.

Challenges and future directions

Despite the potential, ibogaine research faces challenges due to safety concerns and legal restrictions. Most existing data comes from treatments abroad, where clinics charge between $10,000 and $20,000, often requiring cardiac monitoring. The Trump administration's move towards psychedelic research was reportedly influenced by podcaster Joe Rogan, who discussed ibogaine with Trump.

The federal support for ibogaine research marks a significant step towards potentially new treatments for PTSD, reflecting a broader shift in attitudes towards psychedelic therapies.